Pulmonary Fibrosis
Conditions
Keywords
Becacizumab, pulmonary fibrosis, irradiation, chemotherapy
Brief summary
Due to the radiosensitivity of the lung, radiation-induced and chemotherapy-induced pneumonitis and pulmonary fibrosis are frequent happened following cancer therapy. It not only compromise cancer treatment, but also influence patient's life qualities and even death. there are no specific treatment modalities for this treatment-induced complication. Bevasizumab (Avastin), a VEGF inhibitor, can attenuate serum high expression VEGF and pulmonary permeability, maybe effective in the control acute pulmonary fibrosis. Patients will be randomized to receive Bevasizumab (7mg/kg iv) on day one and 21, followed by Dexamethasone （10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20) or Dexamethasone alone. The thoracic CT, plasma TNF-a, IL-6, VEGF and C-reactive protein are accessed on before treatment, 24 hours after Bevasizumab, 7 days, 4 and 8 weeks. the target sample size is 30 cases.
Interventions
DRUGDexamethasone
Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
DRUGBevacizumab
Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
Sponsors
Qingdao Central Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* clinical diagnosed cancer treatment-induced acute pulmonary fibrosis
Exclusion criteria
* chronic pulmonary fibrosis and infection-induced pulmonary fibrosis * active bleeding * uncontrolled high blood pressure * unstable systemic disease * prior exposure to VEGF inhibitor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pulmonary function | up to 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| thoracic CT scan | up to 8 weeks |
Countries
China
Contacts
Primary Contactyouxin ji, md
Outcome results
None listed